Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. // The Lancet Rheumatology. – URL: https://www.sciencedirect.com/science/article/pii/S2665991326003152?dgcid=rss_sd_all
Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Rheumatology. https://www.sciencedirect.com/science/article/pii/S2665991326003152?dgcid=rss_sd_all
“Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.” The Lancet Rheumatology.
@article{article69230,
title = {Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial},
journal = {The Lancet Rheumatology},
url = {https://www.sciencedirect.com/science/article/pii/S2665991326003152?dgcid=rss_sd_all}
}